从“个体化”到“精准化”的肿瘤免疫细胞治疗  

Adoptive immune cell therapy for malignant tumors moves from “individualization” to “precision”

作　　者：黄迪[1] 龚畅[1] 宋尔卫[1,2] HUANG Di;GONG Chang;SONG Er-Wei(Breast Tumor Center,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University,Guangzhou 510120,China;Zhongshan School of Medicine,Sun Yat-Sen University,Guangzhou 510080,China)

机构地区：[1]中山大学孙逸仙纪念医院乳腺肿瘤中心,广东省恶性肿瘤表观遗传与基因调控重点实验室,广州510120 [2]中山大学中山医学院,广州510080

出　　处：《生命科学》2019年第7期651-659,共9页Chinese Bulletin of Life Sciences

基　　金：国家重点研发计划项目(2016YFC1302300);国家自然科学基金项目(81720108029,81621004,81490750,81672594,81772836,81872139,81802643);广东省科技计划项目(2016B030229004);广东省重点实验室项目(2017B030314026);广东省自然科学基金项目(2018A030310085);广州市科技计划项目(健康医疗协同创新重大专项滚动支出项目)(201803040015);广州再生医学与健康广东省实验室临床创新研究项目(2018GZR0201004)

摘　　要：近年来,肿瘤免疫治疗在多种恶性肿瘤中显示了确切的临床疗效,主要包括免疫检查点抑制剂和免疫细胞治疗。其中,肿瘤的免疫细胞治疗是通过回输激活的免疫细胞来介导抗肿瘤的免疫反应,以达到治疗肿瘤的目的。肿瘤细胞免疫治疗经历了从广泛性杀伤到肿瘤特异性杀伤的个体化模式的转变,而随着对实体肿瘤高度异质性的深入认识,肿瘤免疫细胞治疗更趋向于"精准化"。现综述细胞免疫治疗的分类及目前面临的困境,并探索细胞免疫在抗肿瘤治疗中的未来发展趋势。Immunotherapy, including immune checkpoint inhibitors and adoptive cell therapy(ACT), is an effective anti-cancer therapy for various malignant tumors. ACT is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. During the evolvement of ACT, cellular immunotherapy has experienced the individual pattern moving from extensive killing to tumor-specific killing. With the deep understanding of the high heterogeneity of solid tumors, precision immunotherapy is changing the landscape of cancer immunotherapy. In the current review, we describe the classification of cellular immunotherapy. The future directions and unresolved dilemmas of cellular immunotherapy are also discussed.

关 键 词：肿瘤免疫治疗 免疫细胞治疗 免疫抑制 

分 类 号：R197.3[医药卫生—卫生事业管理] R730.3[医药卫生—公共卫生与预防医学]